Trevena Inc. (NASDAQ: TRVN) stock declined by 8.09% at last close whereas the TRVN stock-price gains by 8.8% in the after-hours trading. Trevena, Inc. is a pharmaceutical firm specializing on the discovery and marketing of novel treatments for people suffering from CNS diseases.
TRVN stock, Recent Development
The first COVID-19 patient has been recruited in the NIH-funded ACTIV-4 Host Tissue study, according to Trevena.
China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal
Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.
Simply click here and the name & trading symbol are yours.
The ACTIV-4 Host Tissue study is evaluating four experimental medicines to treat COVID-19-induced dysregulation of the renin-angiotensin-aldosterone system (RAAS) and immune system. TRV027 is a new AT1 receptor-specific agonist that binds to AT1 receptor activity in the RAAS and rebalances it. It works by inhibiting the destructive route that causes acute lung problems and irregular blood clotting while stimulating the cellular pathway that focuses reparative activities that enhance lung function and boost anti-inflammatory efficacy.
Approximately 1,600 patients will be enrolled in the research, which will take place at more than 50 locations across the United States. TRV027 is one of the first research arms to be added to the trial, and other study arms will be added over time. The effect of each treatment on recovery, supplementary oxygen usage, the requirement for mechanical ventilation, organ failure, and mortality is being assessed in this study.
Carrie Bourdow, President and CEO of TRVN stock stated,
COVID-19 has no one cure, and they are proud to be a part of the worldwide effort to combat the epidemic and reduce its long-term effects on populations. TRV027 is one of the first active treatment arms accessible for patient randomization, and he is delighted that patients are already being recruited in this trial.
Sean Collins, Principal Investigator of the ACTIV-4 Host Tissue trial commented,
The discovery of treatments to counteract the coronavirus’s vascular, fibrotic, and inflammatory effects remains a major goal as the COVID-19 pandemic progresses. He added that he is thrilled to report that they’ve recruited their first patient in the ACTIV-4 Host Tissue study, and he is excited to learn more about TRV027’s ability to regulate the RAAS and enhance outcomes for COVID-19 patients.